Skip to main content
Fig. 3 | BMC Medicine

Fig. 3

From: Serological study of CoronaVac vaccine and booster doses in Chile: immunogenicity and persistence of anti-SARS-CoV-2 spike antibodies

Fig. 3

Comparison of antibody response to CoronaVac and BNT162b2 vaccines over time and range of age. Healthy participants from study group 2 received a complete vaccination scheme, and serum samples were collected after the second dose at the indicated time. Forty-four individuals vaccinated with CoronaVac (black) and 20 with BNT162b2 (green). A Direct comparison between the antibody titers against SARS-CoV-2 S protein of CoronaVac or BNT162b2 vaccine. B Correlation between age and antibody titers of individuals vaccinated with CoronaVac and BNT162b from the serum of first 45 days. Each dot represents a single serum sample. C, D Antibody titers from 138 samples collected more than 80 days after the second dose. C Samples from 13 to 45 days were compared to samples from more than 80 days from CoronaVac (black) or BNT162b2 (green) vaccine scheme. D Correlation between age and antibody titers of individuals vaccinated with CoronaVac and BNT162b along time. Each dot represents a serum sample. ****p < .0001, ***p < .001, *p < .05

Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us